首页> 美国卫生研究院文献>Journal of Clinical and Diagnostic Research : JCDR >Salvage Surgery for Metastatic Gall Bladder Cancer with Vanishing Liver Metastasis Following Palliative 5-Fluorouracil Metronomic Chemotherapy
【2h】

Salvage Surgery for Metastatic Gall Bladder Cancer with Vanishing Liver Metastasis Following Palliative 5-Fluorouracil Metronomic Chemotherapy

机译:姑息性5-氟尿嘧啶基因组化学疗法治疗肝转移消失的转移性胆囊癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gall Bladder Cancer (GBC) is an aggressive malignancy. The prognosis of metastatic GBC is dismal. Until recently, there are no standard treatment guidelines for management of patients with metastatic GBC. But the ultimate aim of any treatment modality is to improve the overall survival with good quality of life. We hereby report a long term survivor of metastatic GBC treated with initial six cycles of gemcitabine + cisplatin combination chemotherapy, but did not show any response. In view of chemotoxicity and as a matter of physician preference patient was started on low dose weekly 5- Fluorouracil monotherapy based on a metronomic chemotherapy principle. There was complete resolution of all the liver metastasis and salvage radical cholecystectomy was done. The patient is disease free on imaging at eight months of follow up. A very few such cases have been reported in the world literature, till date.Metastatic disease must not be considered incurable as there are no objective measures to predict tumour biology. Further research on metronomic chemotherapy and tumour genetics in such patients will open a new era of individualised cancer therapy based on objective measures that will predict tumour biology.
机译:胆囊癌(GBC)是一种恶性肿瘤。转移性GBC的预后令人沮丧。直到最近,还没有用于治疗转移性GBC患者的标准治疗指南。但是,任何一种治疗方式的最终目的都是为了提高整体生存率并改善生活质量。我们特此报告吉西他滨+顺铂联合化疗的最初六个周期治疗的转移性GBC的长期幸存者,但未显示任何反应。考虑到化学毒性,并且根据医生的偏爱,患者开始使用基于节律化疗原则的低剂量每周5-氟尿嘧啶单药治疗。所有肝脏转移均已完全解决,并进行了挽救性根治性胆囊切除术。随访八个月,患者影像学检查无疾病。迄今为止,在世界文献中已经报道了极少数这样的病例。由于没有客观的方法来预测肿瘤生物学,因此不能将转移性疾病视为不可治愈的疾病。在此类患者中进行的节拍化学疗法和肿瘤遗传学的进一步研究将基于预测肿瘤生物学的客观指标,开启个性化癌症治疗的新时代。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号